EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Study on the Pharmacological Effects and Mechanism of Rhodojaponin III in Rheumatoid Arthritis

Xiaorong Liu, Shuofu Li, Yin Xu, Wenya Mei, Ribao Zhou

Frontiers in Bioscience-Landmark · 2023

DOI: 10.31083/j.fbl2812337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2023. Verfasst von Xiaorong Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Hunan University of Chinese Medicine, 410208 Changsha, Hunan, China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Arthritis, Experimental. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hunan Province, Project of Hunan Provincial Health and Health Commission, Project of Hunan Provincial Student Innovation and Entrepreneurship Training Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rheumatoid arthritis (RA) is a chronic inflammatory disease with a high rate of disability accompanied by various complications. The pathogenesis of RA is complex with multiple targets and links. This study aims to investigate pharmacological effects and mechanism of Rhodojaponin III in RA.

Methods

The bovine type II collagen-induced arthritis (CIA) rat model and tumor necrosis factor-alpha (TNF-α) induced human umbilical vein endothelial cells (HUVECs) model were constructed. Different concentrations of Rhodojaponin III were utilized for intervention. The progression of CIA was assessed by the arthritis index (AI). Pathological changes in knee joints and synovium were observed. The expressions of angiogenesis-related cytokines were detected. The proliferation, migration, invasion, and angiogenesis of HUVECs were detected. The levels of pro-inflammatory cytokines were determined. The expressions of nuclear factor kappa B-inducing kinase (NIK) pathway-related proteins were analyzed. The binding of Rhodojaponin III to NIK was simulated by molecular docking.

Results

Rhodojaponin III suppressed cartilage damage and bone erosion in the knee joints. Rhodojaponin III inhibited expressions of platelet endothelial cell adhesion molecule-1 (CD31) and vascular endothelial cell growth factor (VEGF) to decrease vascular density. Rhodojaponin III suppressed the proliferation, migration, invasion, and angiogenesis of HUVECs, and decreased the levels of interleukin (IL)-6, IL-1β, and TNF-α. Molecular docking showed that Rhodojaponin III could spontaneously bind to NIK. Rhodojaponin III decreased the expression of NIK, p52, and C-X-C motif chemokine ligand 12 (CXCL12) and the phosphorylation level of IκB kinase-alpha (IKKα) in the synovium of CIA rats and TNF-α-induced HUVECs. NIK overexpression reversed the inhibitory effect of Rhodojaponin III on activation of the NIK/NF-κB pathway, migration, invasion, and angiogenesis of HUVECs, and the secretion of pro-inflammatory cytokines.

Conclusions

Rhodojaponin III affected the angiogenesis and inflammation of CIA rats and TNF-α-induced HUVECs by regulating the NIK/IKKα/CXCL12 pathway. These findings suggest that Rhodojaponin III has potential as a therapeutic agent for RA. Further studies are needed to explore its precise mechanism of action and evaluate its clinical efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidArthritis, ExperimentalRatsHumansAnimalsCattleTumor Necrosis Factor-alphaI-kappa B KinaseMolecular Docking SimulationCytokinesNF-kappa BHuman Umbilical Vein Endothelial CellsDiterpenes

Stichwörter der Autor:innen

Rhodojaponin IIIangiogenesisinflammationnuclear factor kappa B-inducing kinaserheumatoid arthritis

Substanzen

Tumor Necrosis Factor-alphaI-kappa B KinaseCytokinesNF-kappa Brhodojaponin IIIDiterpenes

Autor:innen und Institutionen

  • College of Pharmacy, Hunan University of Chinese Medicine, 410208 Changsha, Hunan, China.
  • Department of Orthopaedics, The First Hospital of Hunan University of Chinese Medicine, 410007 Changsha, Hunan, China.
  • Department of Gastroenterology, The First Hospital of Hunan University of Chinese Medicine, 410007 Changsha, Hunan, China.

Förderung

  • Natural Science Foundation of Hunan Province
  • Project of Hunan Provincial Health and Health Commission
  • Project of Hunan Provincial Student Innovation and Entrepreneurship Training Program
  • Scientific research project of Hunan Provincial Education Department
  • Hunan Provincial Administration of Traditional Chinese Medicine Scientific Research Program
  • Hunan University of Traditional Chinese Medicine Primary Discipline Open Fund Project in Chinese Medicine
  • Hunan University of Traditional Chinese Medicine Youth Program
  • Key Discipline Project on Chinese Pharmacology of Hunan University of Chinese Medicine

Zitieren

APA

Liu, X., Li, S., Xu, Y., Mei, W., & Zhou, R. (2023). A Study on the Pharmacological Effects and Mechanism of Rhodojaponin III in Rheumatoid Arthritis. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2812337

Vancouver

Liu X, Li S, Xu Y, Mei W, Zhou R. A Study on the Pharmacological Effects and Mechanism of Rhodojaponin III in Rheumatoid Arthritis. Frontiers in Bioscience-Landmark. 2023. doi:10.31083/j.fbl2812337

BibTeX
@article{Liu2023,
  author = {Liu, Xiaorong and Li, Shuofu and Xu, Yin and Mei, Wenya and Zhou, Ribao},
  title = {A Study on the Pharmacological Effects and Mechanism of Rhodojaponin III in Rheumatoid Arthritis},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2023},
  doi = {10.31083/j.fbl2812337}
}
Kostenlos starten →